局灶不可逆电穿孔作为局限性前列腺癌初始治疗
本研究评估局灶不可逆电穿孔(IRE)作为局限性前列腺癌初始治疗的安全性、生活质量和短期肿瘤学结局,并分析肿瘤学失败的危险因素。63例符合共识标准的患者接受治疗,无高级别不良事件,性生活质量轻度下降,6-12个月前列腺特异性抗原(PSA)较基线下降70%。随访活检靶区内和全腺肿瘤控制率分别为84%和76%,排除窄安全边缘和系统错误病例后升至97%和87%。
要点
- 局灶IRE治疗后无高级别不良事件,多数生活质量领域无显著变化。
- 性生活质量领域评分从中位66降至54(6个月时),P<0.001。
- 窄安全边缘(P=0.047)和系统错误(P=0.010)是靶区内肿瘤学失败的潜在早期危险因素。
核心结论
- 数据支持局灶IRE作为经严格筛选的局限性前列腺癌患者的初始治疗具有安全性和可行性,并实现有效的短期肿瘤学控制。
研究设计与样本
- 符合原发局灶治疗患者标准和选择方法共识指南的患者纳入分析,接受局灶IRE治疗器官局限的临床显著前列腺癌(定义为高体积Gleason评分6分(ISUP分级1级)或任何Gleason评分7分(ISUP分级2-3级)),分析至少6个月随访的肿瘤学、不良事件和生活质量结局数据。
- 共63例患者符合所有入选标准并纳入最终分析。
主要发现
- 无高级别不良事件发生。
- 生活质量问卷分析显示,躯体(P=0.81)、心理(P=0.48)、肠道(P=0.25)或泌尿生活质量领域(P=0.41和P=0.25)较基线无显著变化,但性生活质量领域轻度下降(基线中位评分66 vs 6个月时54;P<0.001)。
- 与基线相比,6-12个月时前列腺特异性抗原(PSA)水平下降70%(1.8 ng/mL,四分位距0.96-4.8 ng/mL)。
- 窄安全边缘(P=0.047)和系统错误(P=0.010)被确定为靶区内肿瘤学失败的潜在早期危险因素。
- 随访活检靶区内和全腺肿瘤控制率分别为84%(38/45例)和76%(34/45例);排除窄安全边缘和系统错误治疗的患者后,分别升至97%(38/39例)和87%(34/39例)。
关键数值与推荐
- 局灶IRE适用于器官局限的临床显著前列腺癌,定义为高体积Gleason评分6分(ISUP分级1级)或任何Gleason评分7分(ISUP分级2-3级)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the safety, quality of life (QoL) and short-term oncological outcomes of primary focal irreversible electroporation (IRE) for the treatment of localized prostate cancer (PCa), and to identify potential risk factors for oncological failure. PATIENTS AND METHODS: Patients who met the consensus guidelines on patient criteria and selection methods for primary focal therapy were eligible for analysis. Focal IRE was performed for organ-confined clinically significant PCa, defined as high-volume disease with Gleason sum score 6 (International Society of Urological Pathology [ISUP] grade 1) or any Gleason sum score of 7 (ISUP grades 2-3). Oncological, adverse event (AE) and QoL outcome data, with a minimum of 6 months' follow-up, were analysed. Patient characteristics and peri-operative treatment variables were compared between patients with and without oncological failure on follow-up biopsy. Wilcoxon's signed rank test, Wilcoxon's rank sum test and the chi-squared test were used to assess statistically significant differences in paired continuous, unpaired continuous and categorical variables respectively. RESULTS: A total of 63 patients met all eligibility criteria and were included in the final analysis. No high-grade AEs occurred. QoL questionnaire analysis demonstrated no significant change from baseline in physical (P = 0.81), mental (P = 0.48), bowel (P = 0.25) or urinary QoL domains (P = 0.41 and P = 0.25), but there was a mild decrease in the sexual QoL domain (median score 66 at baseline vs 54 at 6 months; P < 0.001). Compared with baseline, a decline of 70% in prostate-specific antigen level (1.8 ng/mL, interquartile range 0.96-4.8 ng/mL) was seen at 6-12 months. A narrow safety margin (P = 0.047) and system errors (P = 0.010) were identified as potential early risk factors for in-field oncological failure. In-field and whole-gland oncological control on follow-up biopsies was 84% (38/45 patients) and 76% (34/45 patients); this increased to 97% (38/39 patients) and 87% (34/39 patients) when patients treated with a narrow safety margin and system errors were excluded. CONCLUSION: Our data support the safety and feasibility of focal IRE as a primary treatment for localized PCa with effective short-term oncological control in carefully selected men.
引用
- van den Bos W, Scheltema MJ, Siriwardana AR, et al. Focal irreversible electroporation as primary treatment for localized prostate cancer. BJU Int. 2017. PMID: 28796935. doi:10.1111/bju.13983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。